The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2019

Filed:

Apr. 27, 2016
Applicants:

Mitsubishi Tanabe Pharma Corporation, Osaka-shi, Osaka, JP;

Osaka University, Suita-shi, Osaka, JP;

National University Corporation Chiba University, Chiba-shi, Chiba, JP;

Inventors:

Motonori Hashimoto, Osaka, JP;

Toshihide Yamashita, Suita, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 25/00 (2006.01); C07K 16/22 (2006.01); A61P 25/02 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/28 (2006.01); A61P 19/02 (2006.01); A61P 17/06 (2006.01); A61P 17/00 (2006.01); A61P 37/00 (2006.01); C12N 5/10 (2006.01); A61K 39/395 (2006.01); C07K 16/46 (2006.01); C12N 15/09 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01); A61P 7/04 (2006.01); A61P 11/06 (2006.01); A61P 1/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61K 39/395 (2013.01); A61P 1/00 (2018.01); A61P 7/04 (2018.01); A61P 11/06 (2018.01); A61P 17/00 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 25/00 (2018.01); A61P 25/02 (2018.01); A61P 25/14 (2018.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01); A61P 27/02 (2018.01); A61P 27/06 (2018.01); A61P 37/00 (2018.01); C07K 16/28 (2013.01); C07K 16/46 (2013.01); C12N 5/10 (2013.01); C12N 15/09 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.


Find Patent Forward Citations

Loading…